Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

To join this study, you would need to be at least 18 years old and have a confirmed diagnosis of Non-Small Cell Lung Cancer with the specific KRAS G12C genetic change. Your cancer also needs to be measurable on scans. You should generally be well enough to carry out most daily activities without much difficulty, which doctors call an ECOG performance status of 0 or 1. You must also have sufficient organ function (like your liver and kidneys) and have recovered from side effects of any previous treatments.

There are also some reasons why you might not be able to join. For example, if you've had certain other cancers recently, received anti-cancer treatment in the last four weeks, or had major surgery recently. You wouldn't be eligible if you have certain active infections (like Hepatitis B or C, or HIV), significant heart or lung conditions, uncontrolled brain spread from your cancer, or if you can't swallow tablets. Women who are pregnant or breastfeeding cannot participate.

To ensure your safety, there are also checks to make sure you haven't recently used certain medications or have specific skin conditions. The medical team will review all your information carefully to determine if this study is suitable for you.

If you join this study, you'll be taking medications by mouth (tablets or capsules). The exact number of visits and tests will vary, but typically involves regular hospital appointments for check-ups, blood tests, and scans to monitor your health and how the treatment is working. You'll be closely watched for any side effects. You'll also need to commit to using effective contraception throughout the study if you are able to have children. The total duration of your participation will depend on how you respond to the treatment and the study's protocol, but there will be ongoing follow-up to monitor your progress and health.